AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAR 12 - (NewsRx.com & NewsRx.net) -- Recent progress in herpes simplex virus vaccine research has been been reviewed recently.
According to researchers from the United States, "Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) cause prevalent, chronic infections that have serious outcomes in some individuals. Neonatal herpes may occur when the infant traverses the cervix during maternal genital herpes. Genital herpes is a major risk factor for human immunodeficiency virus type 1 transmission."
"Considerable efforts have been made to design and test vaccines for HSV, focusing on genital infection with HSV-2," said David M. Koelle and Lawrence Corey at the University of Washington in Seattle. "Several protein subunit vaccines based on HSV-2 envelope glycoproteins have reached advanced-phase clinical trials. These antigens were chosen because they are the targets of neutralizing-antibody responses and because they elicit cellular immunity."
"Encouraging results have been reported in studies of treatment of HSV-seronegative women with a vaccine consisting of truncated glycoprotein D of HSV-2 and a novel adjuvant," stated Koelle and Corey. "Because most sexual HSV transmission occurs during asymptomatic shedding, it is important to evaluate the impact of vaccination on HSV-2 infection, ...
Source: HighBeam Research, Review covers recent progress in herpes simplex virus vaccine...